Immuno-oncology evolution: Implications for pharma market researchers

In association with PMGroup

Immuno-oncology therapies that harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. Until recently only a few products had reached the market for a limited number of indications. However, over the past 12 months, several new products have been approved for a wider range of tumour types and with numerous other products in the pipeline, the competition looks set to hot up.

In association with PMGroup

Watch the webcast, in which oncology market research experts Sue Marett, Phil Rosenberg and Claire Fradet Aubignat will explore the key features of the immuno-oncology market and outline the critical success factors that manufacturers need to consider in order to remain competitive.

What are the key takeaways?

Setting the context: The current situation in immuno-oncology and challenges and opportunities for new targeted therapies entering the market.
Portfolio Panning: Understanding where to invest in the early stages of new product development in order to achieve your objectives.
Marketing and communications: Considerations for the positioning and marketing communications strategy with regards to the evolution of each indication. How this will impact your market research needs.
Biomarker strategies: The impact of biomarker availability on patient selection and sequencing. How to ensure your biomarker strategies are optimised for your brand.

Watch the webcast

Webcast: Immuno-oncology's evolution: Implications for pharma market researchers

Sign up to receive Rapport

Webcast: Immuno-oncology's evolution: Implications for pharma market researchers

Form Header

Form Header

Sign up to receive Rapport